You are here: Industry Insights > Products Guide > Urgent Sourcing Needs of【CPhI.cn】2017.10.23

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Avatrombopag Maleate

BioHub® Magnetic Separator

Avatrombopag

Ursodeoxycholic acid

Troxerutin

CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Urgent Sourcing Needs of【CPhI.cn】2017.10.23

en-cphi.cnOctober 23, 2017

Tag: urgent , Sourcing Needs , CPhI

Favorites

【CPhI.cn】provides the free-of-charge One-to-One Matching Service every week. Your dedicated client service officer collects your sourcing needs and searches suitable suppliers for you to improve your sourcing efficiency greatly.

The validity of the sourcing needs lasts one week.

If your company could provide the following surgical equipment and supplies, you can email the product name to Miki. She will reply you with the detailed information including the buyers' contact information.

Contact Person: Miki

Email: Miki.Zhou@ubmsinoexpo.com

Tel: 86-21-33392254

Name of the Product	CAS No.	Quantity	Details	Country
2-(p-nonylphenoxy)ethanol	96827-63-3		Quantity: 100gQuality Standards: provide purity detailsPacking: depending on stability of compoundPlace of Origin: unimportantPurity: provide purity detailsStandard: goodDetailed Description: Enquiry about cost of product and shipment to a UK University based in London, England.	United Kingdom
L-Histidine methyl ester dihydrochloride L-组氨酸甲酯二盐酸盐 [ān] [zhǐ]	7389-87-9	100	Regular requirement of 100kg/month, please send your quote.	India
Fmoc-(tBu)-L-tyrosine Fmoc 有机合成 - L -酪氨酸	71989-38-3	100	Regular requirement of 100kg/month, please send your quote.	India
N-Boc-O-Benzyl-L-serine N-BOC-O-苄基-L-丝氨酸 [biàn]	23680-31-1	100	Regular requirement of 100kg/month, please send your quote.	India
S-Acetamidomethyl-L-cysteine HCl S-乙酰半胱氨酸盐酸 [xiān]	28798-28-9	100	Regular requirement of 100kg/month, please send your quote.	India
Boc-S-acetamidomethyl-L-cysteine	19746-37-3	100	Regular requirement of 100kg/month, please send your quote.	India
Fmoc-S-acetamidomethyl-L-cysteine 芴甲氧羰基-S-乙酰氨甲基-L-半胱氨酸 [wù] [tāng]	86060-81-3	100	Regular requirement of 100kg/month, please send your quote.	India
O-Benzyl-L-tyrosine O-苄基-L-酪氨酸	16652-64-5	100	Regular requirement of 100kg/month, please send your quote.	India
Fmoc-(t-Bu) L-tyrosine L-酪氨酸	71989-38-3	100	Regular requirement of 100kg/month, please send your quote.	India 印度

Previous:NICE says no for Opdivo in urothelial carcinoma

Next:30 million newborns could die by 2030: UNICEF study

Research and Application of Artemisia Argyi

XiaonishaAugust 12, 2024

Mugwort, also known as fragrant mugwort or Artemisia argyi, is a herbaceous plant belonging to the Compositae family.

Research Progress on the Application of Biologics in Pediatric Asthma

XiaomichongJuly 19, 2024

Research Progress on the Pharmacological Effects and New Drug Forms of Artemisinin and Its Derivatives

XiaomichongJuly 19, 2024

Urgent Sourcing Needs of【CPhI.cn】2017.10.23 | Pharmasources.com

Research and Development Status and Progress of Antibody Technology (Part Ⅱ)

XiaomichongJuly 18, 2024

Antibody-based biological therapeutic drugs have been playing an increasingly important role in biopharmaceuticals due to their strong targeting, good specificity, and significant therapeutic effects.

Urgent Sourcing Needs of【CPhI.cn】2017.10.23

Related News

Research and Application of Artemisia Argyi

Research Progress on the Application of Biologics in Pediatric Asthma

Research Progress on the Pharmacological Effects and New Drug Forms of Artemisinin and Its Derivatives

Research and Development Status and Progress of Antibody Technology (Part Ⅱ)

You may like
More>>

Urgent Sourcing Needs of【CPhI.cn】2017.10.23

Related News

Research and Application of Artemisia Argyi

Research Progress on the Application of Biologics in Pediatric Asthma

Research Progress on the Pharmacological Effects and New Drug Forms of Artemisinin and Its Derivatives

Research and Development Status and Progress of Antibody Technology (Part Ⅱ)

You may likeMore>>

You may like
More>>